BD Regulatory Policy Easing, Overseas Expansion Models Diverge, Four Companies Recommended for Strong Buy
AI summary card
BD Regulatory Policy Easing, Overseas Expansion Models Diverge, Four Companies Recommended for Strong Buy
Citigroup cites expert views on regulatory policy, confirming that biotech export restrictions will focus on a few core technologies rather than broadly affecting conventional BD transactions; companies with offshore IP and clinical data face the lowest risk, with Hengrui, CSPC, Gilead, and Innovent receiving buy ratings.
- Regulatory logic focuses on national security, strictly controlling the transfer of entire domestic core platforms and original disruptive technologies
- Technologies originating overseas but enhanced domestically, such as CAR-T, typically fall outside strict control
- Companies with offshore IP structure, offshore clinical data, and single-asset licensing models (e.g., Gilead) benefit most
- Hengrui, CSPC, Gilead, and Innovent are preferred, with the report suggesting market overreaction provides a good buying opportunity
- Policy details expected to be released by end of 2026, with Ministry of Commerce (MOFCOM) as the approval body
Report interpretation
Overview
This report is a policy study focusing on recent market concerns regarding China's biomedical technology export control rumors. Citigroup invited a senior pharmaceutical innovation policy expert for a conference call to clarify that the regulatory intent is not to fully restrict overseas expansion but to precisely manage the outflow of core technology platforms related to national drug and medical device supply chain security. Based on this, the report reiterates its 'buy' ratings for Hengrui Medicine, CSPC Pharmaceutical, Gilead Sciences, and Innovent Biologics, believing current market sentiment is overly pessimistic and presents a good investment opportunity.
Core views
The core view of the report is that regulation will remain cautious and pragmatic. The expert pointed out that regulators have recognized that the industry's core competitiveness lies in efficient clinical validation capabilities rather than underlying technology invention, thus continuing to encourage compliant outbound licensing of innovative drugs. What is termed 'restrictions' apply only to extreme cases, i.e., full domestic R&D core technology platforms being transferred overseas. For globally leading, China-originated disruptive technologies (such as certain gene therapies), although they may face stricter reviews, technologies like CAR-T originating overseas but optimized domestically are generally exempt. In terms of implementation, exclusive technology licensing and critical health data exports may require review by the Ministry of Commerce (MOFCOM), but most routine BD transactions do not require approval. Most importantly, companies retaining Chinese equity while licensing overseas markets will face significantly reduced regulatory risks.
Analysis framework
The report adopts an analytical framework of 'policy intent – regulatory logic – execution path – company mapping'. First, it clarifies the underlying motives for policy issuance (ensuring domestic pharmaceutical supply chain security), then derives the precise nature of regulation (not blanket but focused on 'core platforms' and 'original disruptive technologies'), followed by specific implementation mechanisms (MOFCOM approval, asset-based triggers rather than transaction value thresholds), and finally maps these to different companies' risk exposures based on their structures (domestic vs offshore registration, domestic vs offshore data). This top-down approach from macro-policy to micro-company application helps investors understand that regulation does not hinder globalization but guides it toward more sustainable development.
Methodology notes
By interpreting the underlying logic of regulatory policies (national security), applicable boundaries (core platforms/original technologies), and implementation details (approval bodies, trigger conditions), assess their impact on actual corporate operations.
This method does not rely on financial modeling but delves into policy texts and expert interviews to determine the true objectives and feasibility of regulations, distinguishing between 'paper risks' and 'substantive impacts', thereby avoiding misinterpretation of policies that could lead to missed investment opportunities.
Asset mapping & comparison
Structured mapping from thesis to named assets (strengths, weaknesses, peers, risks).
- Hengrui Medicine (1276.HK / 600276.SS)Representative mature pharmaceutical company with domestic core IP and clinical data, highest compliance pressure but solid operational foundation
- Strengths
- Stable cash flow, extensive sales network, rich R&D pipeline, and long A-share listing history
- Weaknesses
- IP and clinical data mainly registered domestically, BD structure requires redesigning to comply with new rules
- Comparison
- Compared to offshore architecture companies like Gilead, its regulatory compliance cost is higher, but risk resilience and profit certainty are stronger
- Risks
- R&D/clinical failure, pressure from centralized procurement price cuts, obstacles to overseas expansion, tariff risks
- CSPC Pharmaceutical (1093.HK)Integrated pharmaceutical enterprise balancing raw materials and finished medicines, facing moderate compliance adjustment needs
- Strengths
- Multi-segment business (finished medicines, raw materials, net cash) provides valuation support, new drug launches could boost sales
- Weaknesses
- New drug sales below expectations, continuous price declines, overall pharmaceutical market slowdown
- Comparison
- More stable compared to pure Biotech; less internationalized and smaller BD scale than Hengrui
- Risks
- Slow new drug launch progress, price drops, further weakening of the pharmaceutical market
- Gilead Sciences (1672.HK)Offshore architecture Biotech exemplar, with IP and clinical data entirely overseas, lowest regulatory risk
- Strengths
- Fully avoids domestic data and technology export regulation, high freedom in BD transactions, significant valuation elasticity
- Weaknesses
- Not yet profitable, high uncertainty in clinical development, risks of ASC30/ASC47 clinical failures
- Comparison
- In this policy context, its structural advantages are most pronounced, making it both the 'least damaged' and 'biggest beneficiary'
- Risks
- Lack of profitability, underperformance in sales, core product clinical failure, geopolitical impacts on BD partnerships
- Innovent Biologics (1801.HK)R&D-driven Biotech, focusing on hot areas like obesity, facing dual challenges from competition and regulation
- Strengths
- Potentially huge potential from key products like IBI362, internationally recognized R&D capability
- Weaknesses
- Unprofitable throughout historical and forecast periods, high sales uncertainty, fierce competition in obesity sector
- Comparison
- Similar to Gilead among Biotechs, but its core assets (e.g., PD-1) are commercialized domestically, some aspects still subject to regulatory scrutiny
- Risks
- Lack of profitability, underperformance in sales, fierce competition in obesity sector, R&D failure, regulatory risks
Key data
- Gilead Sciences Target PriceHK$32Based on DCF model, assuming terminal growth rate of 2.0%, WACC of 10.6%
- Innovent Biologics Target PriceHK$115Based on DCF model, assuming terminal growth rate of 4%, WACC of 9.5%
- Hengrui Medicine (HK) Target PriceHK$134Based on DCF model, assuming terminal growth rate of 4%, WACC of 7.9%
- Hengrui Medicine (A-share) Target PriceRMB123Based on DCF model, assuming terminal growth rate of 4%, WACC of 7.9%
Impact & implications
This policy interpretation implies that China’s innovative pharmaceutical companies' global expansion process will not be interrupted but will enter a new phase characterized by greater standardization and sustainability. For enterprises with mature offshore structures (IP registration, clinical trial locations, commercial rights segmentation), such as Gilead Sciences, their BD models will be largely unaffected by the new policy, potentially gaining valuation repair opportunities due to market overreaction. For large domestic pharmaceutical companies like Hengrui Medicine, BD structures need to be restructured to meet compliance requirements, bringing short-term costs but improving long-term credibility and efficiency in global cooperation. Overall, the policy will accelerate industry differentiation, with companies possessing international governance capabilities benefiting significantly.
Risks
- Uncertainty in final policy details, possibly stricter than current expectations
- MOFCOM lacks expertise in frontier biotechnology review, leading to potential delays or deviations in approval processes
- Geopolitical risks may disrupt BD collaborations, especially involving key markets like US-China
What to watch
- Official technical export control directory issued by end of 2026
- First list of external expert review committees announced by Ministry of Commerce (MOFCOM)
- Subsequent disclosure by Hengrui, CSPC, and other companies of BD transaction structure compliance adjustments